NRIX stock forecast, quote, news & analysis
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases... Show more
Nurix Therapeutics (NRIX) Stock Analysis: Pipeline Momentum Meets Earnings Hurdles
Key Takeaways
- Nurix Therapeutics reported Q1 2026 net loss of $87.2 million with revenue of $6.3 million, missing estimates, yet ended with $540.7 million in cash.
- Stock trades around $15.60 amid 52-week range of $8.18-$22.50, down recently but up 68% over past year.
- Analysts maintain Strong Buy consensus with average price target of $30, signaling potential upside.
- Key pipeline advances include multiple AACR 2026 presentations and investor conference participation.
- Targeted protein degradation platform progresses with bexobrutideg (NX-5948) in Phase 2 trials for B-cell malignancies.
Current Market Snapshot
In recent trading sessions, Nurix Therapeutics (NRIX) stock has navigated volatility within its broader uptrend, reflecting investor focus on clinical-stage biopharma dynamics. The shares have pulled back from yearly highs amid sector pressures but maintain support above key lows, buoyed by pipeline optimism. Trading volume has spiked around earnings and conference announcements, underscoring sentiment tied to development milestones rather than immediate profitability. Broader biotech trends, including interest in targeted protein degradation (a technology that eliminates disease-causing proteins), continue to influence NRIX's position in the latest market cycle.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that analyze and trade thousands of tickers across diverse strategies. These bots employ advanced algorithms, including deep learning and price action analysis, to generate signals in varying market conditions—spanning short-term swings, long-only breakouts, and sector-specific plays like biotech or semiconductors. Recent standouts feature 30-day annualized returns up to 171%, with win rates as high as 100% over select periods (25/25 trades) and others at 88% (15/17 trades), alongside profit factors exceeding 4.0 in volatile environments. Each bot differs in timeframe, risk profile, and focus, such as low-drawdown growth sectors or high-momentum industrials posting up to 80% annualized gains. This dynamic selection highlights bots best suited to current volatility. Investors may explore these for data-driven insights into stocks like NRIX.
Recent Developments Driving NRIX Price Action
Nurix Therapeutics, a clinical-stage biopharmaceutical firm pioneering targeted protein degradation therapies for cancer and autoimmune diseases, has seen its stock react to pipeline visibility and financial updates in recent weeks. On April 8, 2026, the company released Q1 2026 results, posting revenue of $6.3 million—well below the $14.25 million consensus—driven by collaboration agreements, alongside research and development (R&D) expenses of $84.1 million, culminating in a net loss of $87.2 million, or $0.79 per share, wider than the expected $0.76 loss. Despite the miss, cash and marketable securities stood at $540.7 million as of February 28, 2026, providing runway for ongoing trials. The earnings shortfall contributed to intraday pressure, with shares dipping amid heightened volume, though after-hours reaction showed modest resilience at +3.55% initially.
The prior day, April 7, Nurix announced participation in an upcoming investor conference, signaling continued engagement with the Street and potential for pipeline spotlights. Earlier, on March 23, the company revealed multiple presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting, underscoring the depth of its research pipeline—including lead candidate NX-5948 (bexobrutideg), a BTK (Bruton's tyrosine kinase) degrader in Phase 2 for relapsed/refractory B-cell malignancies and autoimmune conditions, alongside NX-2127, NX-1607 (CBL-B inhibitor), and IRAK4 degrader NX-0479/GS-6791 for inflammatory diseases. This news briefly lifted sentiment, aligning with a 6.9% single-session gain noted around late March, as investors weighed scientific leadership against biotech volatility.
Analyst actions reinforced optimism: Needham reiterated Buy with a $26 target on April 8, while H.C. Wainwright held Buy at $32 in March, contributing to a Strong Buy consensus and $30 average target—implying over 90% upside from recent levels. Macro factors, like biotech sector rotation and interest rate sensitivity for cash-rich developers, amplified price swings. Insider selling by Chief Legal Officer Christine Ring (8,148 shares for $124k on April 2) added mild caution, but overall, developments tied price action to progress in degradation tech collaborations with Gilead, Sanofi, and Pfizer, balancing earnings disappointment with trial advancements.
2026 Outlook and Key Factors to Monitor
As Nurix advances through 2026, focus remains on its targeted protein degradation platform, with bexobrutideg (NX-5948) poised for Phase 2 readouts in B-cell malignancies and autoimmune indications, potentially validating oral BTK degradation beyond inhibitors. Earlier goals outlined pivotal trial initiations like DAYBreak for relapsed/refractory CLL (chronic lymphocytic leukemia), alongside expansions for NX-1607 in immuno-oncology and IRAK4 programs with partners. Cash reserves exceeding $540 million support R&D without near-term dilution risks, though burn rates around $84 million quarterly warrant efficiency monitoring.
Industry trends favoring degraders—offering advantages in resistant tumors—present opportunities, tempered by clinical risks like trial enrollment delays or safety signals. Regulatory milestones, such as FDA orphan designations or IND filings, and partnership milestones from Gilead, Sanofi, and Pfizer could drive value. Competitive positioning in oncology and inflammation, macroeconomic biotech funding environment, and macro factors like interest rates impacting valuations are critical. Investors should track AACR data disclosures, conference updates, and Q2 results for pipeline momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
NRIX in -5.43% downward trend, sliding for three consecutive days on June 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NRIX declined for three days, in of 315 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRIX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 10-day moving average for NRIX crossed bearishly below the 50-day moving average on June 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
NRIX broke above its upper Bollinger Band on May 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NRIX entered a downward trend on May 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NRIX's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where NRIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on June 12, 2026. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
NRIX moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.644) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). NRIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (22.026) is also within normal values, averaging (357.550).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders
Industry Biotechnology